{"id":"https://openalex.org/W2080459647","doi":"https://doi.org/10.1111/j.1365-2133.2008.08727.x","title":"Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis","display_name":"Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis","alternate_titles":[],"publication_year":2008,"publication_date":"2008-07-08","ids":{"openalex":"https://openalex.org/W2080459647","doi":"https://doi.org/10.1111/j.1365-2133.2008.08727.x","mag":"2080459647","pmid":"https://pubmed.ncbi.nlm.nih.gov/18627375"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2133.2008.08727.x","doi":"https://doi.org/10.1111/j.1365-2133.2008.08727.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2133.2008.08727.x","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2080459647"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006964107","display_name":"Steven R. Feldman","orcid":"https://orcid.org/0000-0002-0090-6289","observed_orcids":["https://orcid.org/0000-0002-0090-6289"]},"institutions":[{"id":"https://openalex.org/I4405269449","display_name":"Wake Forest University Health Sciences","ror":"https://ror.org/046r1r105","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]},{"id":"https://openalex.org/I47251452","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724","country_code":"US","type":"education","lineage":["https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"S.R. Feldman","raw_affiliation_strings":["Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. sfeldman@wfubmc.edu","Wake Forest University School of Medicine, Medical Center Boulevard, Winston\u2010Salem, NC 27157, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. sfeldman@wfubmc.edu","institution_ids":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]},{"raw_affiliation_string":"Wake Forest University School of Medicine, Medical Center Boulevard, Winston\u2010Salem, NC 27157, U.S.A","institution_ids":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049859852","display_name":"Alice Bendix Gottlieb","orcid":"https://orcid.org/0000-0002-2927-8618","observed_orcids":["https://orcid.org/0000-0002-2927-8618"]},"institutions":[{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A.B. Gottlieb","raw_affiliation_strings":["Department of Dermatology, Tufts\u2010Medical Center, Boston, MA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Tufts\u2010Medical Center, Boston, MA, U.S.A","institution_ids":["https://openalex.org/I1290900354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103805017","display_name":"MEHMET MURAT BALA","orcid":"https://orcid.org/0000-0002-7213-5647","observed_orcids":["https://orcid.org/0000-0002-7213-5647"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Bala","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Services, Malvern, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Services, Malvern, PA, U.S.A","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101732098","display_name":"Ying Wu","orcid":"https://orcid.org/0000-0002-4799-2225","observed_orcids":["https://orcid.org/0000-0002-4799-2225"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Wu","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Services, Malvern, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Services, Malvern, PA, U.S.A","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008820720","display_name":"Debra F. Eisenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D. Eisenberg","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Services, Malvern, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Services, Malvern, PA, U.S.A","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077476041","display_name":"Cynthia A. Guzzo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. Guzzo","raw_affiliation_strings":["Centocor, Inc., Malvern, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centocor, Inc., Malvern, PA, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042835744","display_name":"S. Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Li","raw_affiliation_strings":["Centocor, Inc., Malvern, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centocor, Inc., Malvern, PA, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048778501","display_name":"Lisa T. Dooley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L.T. Dooley","raw_affiliation_strings":["Centocor, Inc., Malvern, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centocor, Inc., Malvern, PA, U.S.A","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075798284","display_name":"Alan Menter","orcid":"https://orcid.org/0000-0002-9314-0007","observed_orcids":["https://orcid.org/0000-0002-9314-0007"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Menter","raw_affiliation_strings":["Baylor Research Institute, Dallas, TX, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Research Institute, Dallas, TX, U.S.A","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5006964107"],"corresponding_institution_ids":["https://openalex.org/I4405269449","https://openalex.org/I47251452"],"apc_list":{"value":3731,"currency":"GBP","value_usd":4920},"apc_paid":null,"fwci":2.1362,"has_fulltext":false,"cited_by_count":88,"citation_normalized_percentile":{"value":0.8655082,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"159","issue":"3","first_page":"704","last_page":"710"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.8980000019073486},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.9909999966621399},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.9900000095367432},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":0.9620000123977661},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.9869999885559082},{"id":"https://openalex.org/keywords/disease-severity","display_name":"disease severity","score":0.8709999918937683},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.6460000276565552},{"id":"https://openalex.org/keywords/treatment-effects","display_name":"treatment effects","score":0.32899999618530273},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.41999998688697815}],"concepts":[{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.9063090085983276},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.8774183392524719},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8015409708023071},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.6422052383422852},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.4495507478713989},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.4324647784233093},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3480515480041504},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29542917013168335},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.19095006585121155},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.06414410471916199}],"mesh":[{"descriptor_ui":"D000069285","descriptor_name":"Infliximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006305","descriptor_name":"Health Status Indicators","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006949","descriptor_name":"Hyperlipidemias","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D011594","descriptor_name":"Psychometrics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012044","descriptor_name":"Regression Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018434","descriptor_name":"Sickness Impact Profile","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2133.2008.08727.x","doi":"https://doi.org/10.1111/j.1365-2133.2008.08727.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2133.2008.08727.x","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:18627375","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18627375","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The British journal of dermatology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W1556049736","https://openalex.org/W1769751039","https://openalex.org/W1777824885","https://openalex.org/W1968610691","https://openalex.org/W1975463338","https://openalex.org/W1994127723","https://openalex.org/W1997732512","https://openalex.org/W2007517418","https://openalex.org/W2022665587","https://openalex.org/W2037377025","https://openalex.org/W2056468769","https://openalex.org/W2056996834","https://openalex.org/W2060886633","https://openalex.org/W2067327580","https://openalex.org/W2078157933","https://openalex.org/W2086861262","https://openalex.org/W2088314729","https://openalex.org/W2088804269","https://openalex.org/W2093615630","https://openalex.org/W2096991001","https://openalex.org/W2135530788","https://openalex.org/W2137755908","https://openalex.org/W2151546682","https://openalex.org/W2161895264","https://openalex.org/W2168911501","https://openalex.org/W2170270641","https://openalex.org/W2204389625","https://openalex.org/W4292806894","https://openalex.org/W6633244019"],"related_works":["https://openalex.org/W2086861262","https://openalex.org/W2170270641","https://openalex.org/W2271791365","https://openalex.org/W2135530788","https://openalex.org/W2092267860","https://openalex.org/W2400007513","https://openalex.org/W2016716920","https://openalex.org/W4231986655","https://openalex.org/W2127833079","https://openalex.org/W3108486099"],"abstract_inverted_index":{"BACKGROUND:":[0],"Psoriasis":[1],"affects":[2],"patients":[3,41,65,86],"both":[4],"physically":[5],"and":[6,21,62,101,105,154,169,176,183,210,229],"psychologically.":[7],"OBJECTIVES:":[8],"To":[9],"investigate":[10],"the":[11,29,73,181,184],"effect":[12,124,145],"of":[13,18,31,125,139,160,180,200,234,242],"comorbidities":[14,127,141],"on":[15,128,142],"health-related":[16],"quality":[17],"life":[19],"(HRQoL)":[20],"to":[22,48,71,89],"determine":[23],"whether":[24],"infliximab":[25,50,90,143,167,195,217],"improved":[26,174,215,239],"HRQoL":[27,106,130,193,209],"in":[28,192],"presence":[30],"these":[32,243],"conditions.":[33],"METHODS:":[34],"In":[35],"this":[36],"multicentre,":[37],"double-blind":[38],"study,":[39],"835":[40],"with":[42,194,216],"moderate-to-severe":[43],"plaque":[44],"psoriasis":[45],"were":[46,66,117,158,213,231],"randomized":[47],"receive":[49,72],"3":[51,168],"or":[52,56,79,204],"5":[53,91,170,218],"mg":[54,92,171,219],"kg(-1)":[55,93,172,220],"placebo":[57,85],"at":[58,68,94,119],"weeks":[59,78],"0,":[60],"2":[61],"6.":[63],"Infliximab-treated":[64],"re-randomized":[67],"week":[69,83,95,165,207],"14":[70],"same":[74],"treatment":[75,144,196],"every":[76,222],"8":[77,223],"as":[80],"needed":[81],"through":[82],"46;":[84],"crossed":[87],"over":[88],"16.":[96],"Disease":[97,150,226],"severity":[98,151],"(Psoriasis":[99],"Area":[100],"Severity":[102],"Index,":[103,110],"PASI)":[104],"(Dermatology":[107],"Life":[108],"Quality":[109],"DLQI;":[111],"36-item":[112],"Short-Form":[113],"Health":[114],"Survey,":[115],"SF-36)":[116],"measured":[118],"various":[120],"time":[121],"points.":[122],"The":[123,137],"patient":[126,202],"baseline":[129,162,201],"was":[131,146,197],"assessed":[132],"using":[133],"multiple":[134],"regression":[135],"models.":[136],"impact":[138],"key":[140],"also":[147],"assessed.":[148],"RESULTS:":[149],"(PASI),":[152],"depression":[153,228],"psoriatic":[155],"arthritis":[156],"(PsA)":[157],"predictors":[159,233],"poor":[161,235],"HRQoL.":[163,236],"At":[164],"10,":[166],"significantly":[173,238],"physical":[175],"mental":[177],"health":[178],"dimensions":[179],"SF-36":[182],"DLQI":[185],"(all":[186],"P":[187],"<":[188],"0.001).":[189],"Consistent":[190],"improvement":[191],"observed":[198],"regardless":[199,241],"characteristics":[203],"comorbidities.":[205],"Through":[206],"50,":[208],"PASI":[211],"scores":[212],"most":[214],"administered":[221],"weeks.":[224],"CONCLUSIONS:":[225],"severity,":[227],"PsA":[230],"significant":[232],"Infliximab":[237],"HRQoL,":[240],"characteristics.":[244]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2080459647","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
